SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.

Shenzhen New Industries Biomedical Engineering Co., Ltd.

300832

CNE100003T39

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 2025-06-19			5-day change	1st Jan Change
58.68 ^CNY	+0.43%		-8.30%	-17.18%

Jun. 02	Shenzhen New Industries Biomedical Engineering Secures Four New Medical Device Approvals in China	MT
Apr. 28	Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 79.59 Yuan From 90.31 Yuan, Keeps at Buy	MT

Shenzhen New Industries Biomedical Engineering Co., Ltd. Proposes Dividend for the Year 2024

Published on 04/27/2025 at 18:00

Shenzhen New Industries Biomedical Engineering Co., Ltd. proposed Cash dividend/10 shares (tax included) of CNY13.00000000 for the year 2024.

Latest news about Shenzhen New Industries Biomedical Engineering Co., Ltd.

Shenzhen New Industries Biomedical Engineering Secures Four New Medical Device Approvals in China	Jun. 02	MT
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 79.59 Yuan From 90.31 Yuan, Keeps at Buy	Apr. 28	MT
New Industries Biomedical Engineering 2024 Net Profit Up 10.6% Y/Y	Apr. 25	RE
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 25	CI
New Industries Biomedical Prelim 2024 Net Profit Up 10.6% Y/Y	Apr. 08	RE
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	Apr. 08	CI
New Industries Biomedical's Shareholder Plans To Unload Up To 1% Stake	Mar. 10	RE
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 90.31 Yuan From 95.79 Yuan, Keeps at Buy	Feb. 19	MT
Shenzhen New Industries Biomedical Engineering Gets Two Medical Device Registration Certificates for Assay Kits	Feb. 13	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 95.79 Yuan From 95.86 Yuan, Keeps at Buy	24-10-16	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Approves Board Appointments	24-09-10	CI
Shenzhen New Industries Biomedical Engineering's H1 Profit Jumps 20%, Operating Income Up 19%	24-08-22	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-22	CI
Shenzhen New Industries Biomedical Engineering Gets Nod to Register Antiphospholipid Assay Kit	24-08-15	MT
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 95.86 Yuan From 93.36 Yuan, Keeps at Buy	24-07-19	MT
Shenzhen New Industries Biomedical Engineering Gets Registration Certificate for Detection Kit	24-06-13	MT
Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 93.36 Yuan From 98.15 Yuan, Keeps at Buy	24-04-26	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-04-25	CI
Shenzhen New Industries Biomedical Engineering Gets Nod to Register Five Devices	24-04-18	MT
Shenzhen New Industries Biomedical Engineering's 2023 Profit Jumps 25%	24-04-11	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	24-04-11	CI
Nomura Adjusts New Industries Biomedical Engineering’s Price Target to 98.15 Yuan From 86.13 Yuan, Keeps at Buy	24-03-12	MT
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 86.13 Yuan From 75.19 Yuan, Keeps at Buy	23-12-18	MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI

Chart Shenzhen New Industries Biomedical Engineering Co., Ltd.

Duration

Period

Chart Shenzhen New Industries Biomedical Engineering Co., Ltd.

300832: Dynamic Chart

Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The Company operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The Company sells its products both in domestic and international markets, including Asia, Europe, America and Africa.

Employees

2,841

Sector

Medical Equipment, Supplies & Distribution

Calendar

Aug. 21 - Q2 2025 Earnings Release (Projected)

More about the company